CytoSorbents Corporation (CTSO)

[andy55q]

New on PubMed !!!

Removal of Bilirubin with a New Adsorbent System: In Vitro Kinetics.
Gemelli C, et al. Blood Purif. 2018.
Authors
Gemelli C1, Cuoghi A1,2, Magnani S3, Atti M3, Ricci D4, Siniscalchi A5, Mancini E4, Faenza S5.
Author information
1
Science and Technology Park for Medicine, Mirandola, Italy.
2
Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Modena, Italy.
3
Aferetica S.r.l, Bologna, Italy.
4
Nephrology, Dialysis, Hypertension Unit, Teaching Hospital Policlinico S.Orsola-Malpighi, Bologna, Italy.
5
Anaesthesiology and Intensive Care Unit, Teaching Hospital Policlinico S.Orsola-Malpighi, Bologna, Italy.
Citation
Blood Purif. 2018 Sep 14:1-6. doi: 10.1159/000492378. [Epub ahead of print]
Abstract
BACKGROUND/AIMS: Many potentially toxic molecules accumulate in the blood during hepatic dysfunction. In clinical practice, it is very difficult to remove bilirubin, the most widely studied toxin, and particularly the unconjugated form, strongly albumin-bound. The aim of this in vitro study was to assess irreversible bilirubin adsorption as a protein-bound compound marker, using Cytosorb® (Cytosorbents Corp.), a new hemoadsorption device designed to remove cytokines.

METHODS: We performed 4 in vitro experiments, dynamic and static, with different albumin-bilirubin solutions.

RESULTS: All experiments showed the resin's ability to break the albumin-bilirubin complex (Experiment 1, 2), leading to efficient bilirubin removal for 24 h (Removal Rate: 90% Experiment 3) with minimal albumin loss. No sign of bilirubin release from the charged resin was detected (Experiment 4).

CONCLUSION: Cytosorb® seems a promising artificial liver support, thanks to its ability to adsorb bilirubin and its proven ability to modulate the cytokines involved in hepatic dysfunction.